Answers are grounded in this paper and cite their sources.
In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety. An unplanned survival analysis showed a benefit for decitabine, which was not observed at the time of the primary analysis.
No takes yet. Share an insight, caveat, or question.
Kantarjian et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: